LY3962673 + Cetuximab + Gemcitabine + nab-paclitaxel + Oxaliplatin + leucovorin + Irinotecan + 5-fluorouracil
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Ductal Adenocarcinoma
Conditions
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer
Trial Timeline
Sep 12, 2024 → Mar 1, 2029
NCT ID
NCT06586515About LY3962673 + Cetuximab + Gemcitabine + nab-paclitaxel + Oxaliplatin + leucovorin + Irinotecan + 5-fluorouracil
LY3962673 + Cetuximab + Gemcitabine + nab-paclitaxel + Oxaliplatin + leucovorin + Irinotecan + 5-fluorouracil is a phase 1 stage product being developed by Eli Lilly for Pancreatic Ductal Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06586515. Target conditions include Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06586515 | Phase 1 | Recruiting |
Competing Products
20 competing products in Pancreatic Ductal Adenocarcinoma